Important declarations

Please remove this info from manuscript text if it is also present there.

Associated Data

Data supplied by the author:

Raw data are available in the Supplemental Files. PRISMA checklist S1 File. COVID-19 or SARS-CoV-2 publications with at least one researcher with Latin American affiliation. S2 File. Genome sequences from Latin American SARS-CoV-2 strains collected in the GISAID database.

Required Statements

Competing Interest statement:

The authors declare that they have no competing interests.

Funding statement:

The authors received no funding for this work.



Contributions of Latin American researchers in the understanding the novel coronavirus outbreak: A literature review

Karen Y Fiesco-Sepúlveda Equal first author, 1, Luis Miguel Serrano-Bermúdez Corresp. Equal first author, 2

Corresponding Author: Luis Miguel Serrano-Bermúdez Email address: Imserranob@unal.edu.co

This paper aimed to give the visibility of Latin American researchers' contributions to the comprehension of COVID-19; our method was a literature review. Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus, SARS-CoV-2, and its disease COVID-19. Therefore, in less than four months, researchers have published a significant number of articles related to this novel virus. For instance, a search focused on the Scopus database on April 10, 2020, showed 1224 documents published by authors with 1797 affiliations from 80 countries. 25.4%, 24.0%, and 12.6% of these national affiliations were from China, Europe, and the USA, respectively, making these regions leaders in COVID-19 research. In the case of Latin America, on April 10, 2020, we searched different databases, such as Scopus, PubMed, and Web of Science, finding that the contribution of this region was 2.7±0.6% of the total publications found. In other words, we found 153 publications related to COVID-19 with at least one Latin American researcher. We summarized and processed the information from these 153 publications, finding active participation in topics like medical, social, and environmental considerations, bioinformatics, and epidemiology.

¹ Epidemiology Program, Faculty of Health Sciences, Universidad Surcolombiana, Neiva, Colombia

² Bioprocesses and Bioprospecting Group, Universidad Nacional de Colombia, Bogotá D.C., Colombia



1 Contributions of Latin American researchers in the

2 understanding the novel coronavirus outbreak: A

3 literature review

4

5

- 6 Karen Y Fiesco-Sepúlveda¹, Luis Miguel Serrano-Bermúdez²
- 7 ¹ Epidemiology Program, Faculty of Health Sciences, Universidad Surcolombiana, Neiva,
- 8 Colombia.
- 9 ² Bioprocesses and Bioprospecting Group, Universidad Nacional de Colombia, Bogotá D.C.,
- 10 Colombia.

- 12 Corresponding Author:
- 13 Luis Miguel Serrano-Bermúdez
- 14 Carrera 30 No. 45-03, Bogotá D.C., 11001, Colombia
- 15 Email address: lmserranob@unal.edu.co (LMSB)



Abstract

17	This paper aimed to give the visibility of Latin American researchers' contributions to the
18	comprehension of COVID-19; our method was a literature review. Currently, the world is facing
19	a health and socioeconomic crisis caused by the novel coronavirus, SARS-CoV-2, and its disease
20	COVID-19. Therefore, in less than four months, researchers have published a significant number
21	of articles related to this novel virus. For instance, a search focused on the Scopus database on
22	April 10, 2020, showed 1224 documents published by authors with 1797 affiliations from 80
23	countries. 25.4%, 24.0%, and 12.6% of these national affiliations were from China, Europe, and
24	the USA, respectively, making these regions leaders in COVID-19 research. In the case of Latin
25	America, on April 10, 2020, we searched different databases, such as Scopus, PubMed, and Web
26	of Science, finding that the contribution of this region was 2.7±0.6% of the total publications
27	found. In other words, we found 153 publications related to COVID-19 with at least one Latin
28	American researcher. We summarized and processed the information from these 153
29	publications, finding active participation in topics like medical, social, and environmental
30	considerations, bioinformatics, and epidemiology.

31

32

1. Introduction

33 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus that mainly
34 affects the respiratory system through the new coronavirus disease 2019 (COVID-19) (Ciotti *et al.*, 2020). COVID-19 has spread quickly; thus, on March 11, 2020, the World Health
36 Organization (WHO) declared it as a pandemic (Hussain *et al.*, 2020). Since the first cases
37 reported in Wuhan, China, in December 2019, until April 20, 2020, SARS-CoV-2 has affected



38	most countries in the world, with nearly 2.5 million people infected and 170,000 deaths (Johns
39	Hopkins University, 2020). Latin America is no stranger to this reality, totaling approximately
40	100,000 cases and 5,500 deaths, as shown in Table 1 (Johns Hopkins University, 2020).
41	However, these data may be lower than actual numbers because the number of tests per million
42	inhabitants remains low, which is caused by factors such as the limited availability of tests and
43	the difficulty of monitoring people without facilities like indigenous populations, vulnerable
44	groups, and Venezuelan refugees (Oliveira et al., 2020; Torres & Sacoto, 2020).
45	SARS-CoV-2, as SARS and MERS, belongs to the family <i>Coronaviridae</i> , has a zoonotic origin,
46	and can remain on some surfaces for considerable periods (Ciotti et al., 2020; van Doremalen et
47	al., 2020). Additionally, COVID-19 is a new disease with no yet vaccines or targeted drugs,
48	making the containment of the outbreak difficult (Carnero Contentti & Correa, 2020). Therefore,
49	the recommendation is the self-isolation to reduce COVID-19 spreading, especially in more
50	susceptible people as older adults or patients with comorbidities (Diaz-Quijano et al., 2020).
51	More general aspects of the current outbreak have been published in review articles according to
52	available information in the moment of publication. These reviews include other zoonotic
53	diseases (such as SARS and MERS), outbreak chronology, virus characteristics, zoonotic links,
54	transmission, diagnosis, disease characteristics, therapeutics & treatments, prevention,
55	epidemiological surveillance, and control (Ciotti et al., 2020; Cupertino et al., 2020; Huang et
56	al., 2020; Millán-Oñate et al., 2020; Palacios Cruz et al., 2020; Rodriguez-Morales et al., 2020a;
57	Sifuentes-Rodriguez & Palacios-Reyes, 2020; Siordia, 2020; Wu et al., 2020; Zhu et al., 2020).
58	In the past, during SARS and MERS outbreaks, research focused on coronaviruses increased
59	significantly, which was led by researchers from China and the USA (Bonilla-Aldana et al.,
60	2020b). This new outbreak is not an exception because thousands of articles have been published



in less than four months, where China, Europe, and the USA are leaders in the number of publications. In the case of Latin America, it is a region with an increasingly high contribution to science; thus, our question was, what are the contributions of Latin American researchers in understanding this novel coronavirus outbreak? Therefore, our purpose in this review was to highlight the contributions of this region in the comprehension of SARS-CoV-2 and COVID-19. The literature survey consisted of revising and summarizing publications with Latin American researchers. Keeping in mind that several researchers from this region work together with researchers from other continents, we included publications submitted by these types of international research groups. Hence, the relevance of this review focused on finding the research interests of Latin American researchers according to global and regional priorities.

2. Survey methodology

2.1. Search strategy

We performed the present review following the PRISMA guidelines. The search was done on April 10, 2020, using Scopus, Web of Science, PubMed, ScienceDirect, Wiley, Sage, LILACS, and SciELO databases because they are the main academic literature collections globally and regionally. Other databases like Springer Link were excluded because they do not allow to filtrate by affiliation. The search equation used had ("COVID 19" OR "COVID-19" OR "SARS-CoV-2" OR "SARS CoV 2" OR "SARS-CoV 2" OR "2019-nCoV" OR "2019 nCoV" OR "nCoV-2019" OR "nCoV 2019" OR "hCoV-19" OR "hCoV 19") in all fields and (Argentina OR Bolivia OR Brasil OR Brazil OR Chile OR Colombia OR Cuba OR Ecuador OR Salvador OR Guatemala OR Haiti OR Honduras OR Mexico OR Nicaragua OR Panama OR Paraguay OR



Peru OR Dominicana OR Uruguay OR Venezuela) in affiliation field. We did not considerpreprints during the search stage. No interfaces were used in the present literature review.

2.2. Article selection and data extraction

After the search stage, both reviewers (KYFS and LMSB) removed all duplicated publications, which included a manual revision because some publications were simultaneously in English, Spanish, or Portuguese. Later, we performed a second manual revision to verify that all publications had at least one researcher with a Latin American affiliation. After these two manual revisions, we did not exclude more publications, and final publications were included in the qualitative synthesis. Before the qualitative synthesis, we collected the following information, which was used in the bibliometric analysis: title, authors, journal, DOI, type of publication, national affiliation of Latin American researchers, and topic of publication.

2.3. Data analysis

We summarized information from the collected publications according to the type of publication, the topic of publication, and the national affiliation in the "Bibliometric analysis" section. The first purpose of this section was to quantify contributions of the region in the global context, and the contribution by country in the regional context. The second purpose was to classify the publications by topic and type, which allowed us to organize the next sections of this literature review. In the following two sections, "Phylogenetic and molecular understanding" and "medical contributions", we compiled information from research articles and reviews. The last section, called "Additional concerns", was included to highlight contributions not covered in the two





main topics, but discussed in the remaining publications (commentaries, letters to the editor, editorials, communications, perspectives, points of view, and contributions).

3. Bibliometric analysis

Following the PRISMA guidelines shown in Figure 1, we found 301 publications in the considered databases; this number decreased to 161 after excluding duplicates. Later, we manually excluded eight additional publications due to affiliations from New Mexico (1) and Pennsylvania (7) were confused with Mexico and Panama, respectively. Therefore, this qualitative analysis included 153 publications, which contained at least one researcher with Latin American affiliation (see Supplementary S1 file for complete information of publications). We highlight that several publications were not exclusively submitted by Latin American researchers, some of which are part of research groups together with North American, European, or Asian researchers. Figure 2 presents the classification of publications by type, where most of them were letters to the editor or commentaries, editorials, and research articles.

Regardless of the number of authors from the same country but different institutions, among all publications, we highlight that 15 of them were submitted by groups in which there were researchers from at least two Latin American countries. Therefore, these publications were counted for each nation involved; thus, these 15 publications have 56 national affiliations. Most of these publications were due to the Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), which was created to integrate the region around this new outbreak (Rodriguez-Morales *et al.*, 2020d). The remaining 138 publications were submitted by groups in which there were researchers from a single Latin American country. Therefore,



128	these publications were counted once for the country, disregarding whether they were submitted
129	by one or more researchers with the same national affiliation; in other words, these 138
130	publications have 138 national affiliations. In summary, the 153 publications accounted for 194
131	national affiliations. Figure 3 shows publications by national affiliation, where Brazil had the
132	highest contribution with 80 publications, followed by Colombia, Mexico, and Argentina, with
133	36, 18, and 14 publications, respectively. Conversely, the following Latin American countries
134	had no publications: Cuba, Costa Rica, Dominican Republic, El Salvador, Guatemala, Haiti, and
135	Nicaragua.
136	We did the same search without the affiliation field restriction. We found 1224, 615, 3538, 1841,
137	665, 48, 2627, and 34 publications in Scopus, Web of Science, PubMed, ScienceDirect, Wiley,
138	Sage, LILACS, and SciELO databases, respectively. Hence, publications with Latin American
139	researchers in these databases, Figure 1, represent 2.9%, 3.1%, 2.8%, 3.3%, 2.9%, 2.1%, 1.6%,
140	and 76.5% of all publications, respectively. Excluding Scielo, which is a Latin American
141	database, the contribution of the region was 2.7±0.6%. This low value could be associated with
142	the science gap (gap in science funding, technology, facilities) between the region and the
143	developed countries. However, other possibilities are the late coronavirus appearance in the
144	region (between February and March), as opposed to the initial outbreak (December 2019) and
145	the number of Latin American cases (nearly 4% world total), as shown in Table 1.
146	Finally, Figure 4 shows the classification of publications by topic, which were medical
147	considerations (surgery recommendations, diagnosis, comorbidities, medical guidelines,
148	dentistry considerations, among others), social and environmental considerations, general aspects
149	(zoonotic links, spreading, origin, disease, surveillance, among others), epidemiological
150	analyses, bioinformatics (molecular and phylogenetic analyses, molecular simulations, genetic



annotations, among others), mental health considerations, search for potential treatments, and meta-analyses. Excluding the general aspects, the remaining topics are shown in the following sections.

154

155

151

152

153

4. Phylogenetic and molecular understanding

The researcher with the highest number of research articles was Ph.D. Marta Giovanetti, who has 156 contributed to SARS-CoV-2 understanding through bioinformatic analyses (Angeletti et al., 157 158 2020; Benvenuto et al., 2020a; Benvenuto et al., 2020b; Benvenuto et al., 2020c; Benvenuto et al., 2020d; Cleemput et al., 2020; Giovanetti et al., 2020a; Giovanetti et al., 2020b). Her first 159 160 research focused on a phylogenetic analysis of SARS-CoV-2, finding that among the viruses compared, this virus is closely related to bat-SL-CoVZXC21 (GenBank ID MG772934.1), while 161 162 the least related is MERS (Benvenuto et al., 2020b). However, Cardenas-Conejo et al. (2020) proposed that SARS-CoV-2 has a closer relation to bat-SL-CoV-RaTG13 (GenBank ID 163 164 MN996532.1), then, authors suggested first that SARS-CoV-2 is unlikely to come directly from pangolin viruses, and second, that if SARS-CoV-2 has a recombinant origin, this recombination 165 166 did not happen in ORF1ab. Nevertheless, both Benvenuto et al. (2020b) and Cardenas-Conejo et al. (2020) concluded that the novel virus could come from a bat SARS-like coronavirus isolate, 167 168 which is in agreement with reports from the GISAID database (Hadfield et al., 2018; Sagulenko 169 et al., 2018). Subsequent studies of the Giovanetti group found differences in the superficial spike protein S of 170 SARS-CoV-2 through structural analyses, which could give a higher ability to infect humans 171 172 when compared to other coronaviruses (Benvenuto et al., 2020b). This ability could be attributed 173 to two mutations found in the non-structural protein 2 (nsp2) and nsp3, both originating from a



174	possible positive pressure (Angeletti et al., 2020). Similarly, evaluating in silico molecular
175	interactions between the human angiotensin-converting enzyme 2 (ACE2) receptor and the spike
176	protein of some coronaviruses, Ortega et al. (2020a) found that SARS-CoV-2 has some modified
177	residues. Such residues could improve the recognition and interaction with the ACE2 receptor,
178	providing SARS-CoV-2 with a higher infectiousness, which is in agreement with another study
179	published simultaneously (Andersen et al., 2020). Likewise, performing in silico molecular
180	interactions, Ortega et al. (2020b) evaluated the interaction between the protease of SARS-CoV-
181	2 and some protease inhibitors as a strategy to control COVID-19 infection. The most energetic
182	interactions predicted were using Saquinavir, Lopinavir, and Tipranavir, which are treatments for
183	HIV patients; however, experimentation is required to validate these simulations.
184	In a later study, the Giovanetti group analyzed SARS-CoV-2 mutations through time, finding
185	two variations located in nsp6 and ORF10, which could be caused by a positive selective
186	pressure, leading to a lower protein structure stability and possibly (awaiting for evidence) a
187	higher virulence (Benvenuto et al., 2020a). Cardenas-Conejo et al. (2020) similarly detected
188	variations in nsp6 and eight deleted amino acids in nsp1 from some Japanese virus strains.
189	Although these in silico studies are a first approach and require experimental validation
190	(Ciccozzi et al., 2020), they could also be a first step to aid in identifying treatments or vaccines.
191	Lastly, Giovanetti simultaneously contributed to another research group to develop and validate
192	an open-access tool, called the Genome Detective Coronavirus Typing Tool, which analyzes
193	SARS-CoV-2 genomes to generate new knowledge of COVID-19 outbreak (Cleemput et al.,
194	2020).
195	Concerning the sequencing of SARS-CoV-2 genomes to understand this novel coronavirus, some
196	Latin American researchers have contributed to the publication of sequences of isolated strains



from countries such as Chile (Castillo *et al.*, 2020) or Nepal (Sah *et al.*, 2020). Researchers from other countries have also sequenced the genomes of strains from Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, and Uruguay, totaling 98 genome sequences until April 20, 2020 (see Supplementary S2 file for detailed information of all sequences). The GISAID database has these 98 sequences collected along with 10,380 others, meaning that Latin American contribution is near 0.94% (Hadfield *et al.*, 2018; Sagulenko *et al.*, 2018). Table 2 summarizes this information by country, showing that Brazil and Mexico have the highest number of sequenced genomes, 52 and 17, respectively. Figure 5 presents some of the Latin American SARS-CoV-2 strains in the phylogenetic tree, evidencing the high heterogeneity among them because they belong to different clades.

5. Medical contributions

5.1. Epidemiological analyses

Studies to track first cases in different countries have been performed, such as the case of tracing the first cases of COVID-19 in countries like Italy (Giovanetti *et al.*, 2020b) and Chile (Castillo *et al.*, 2020) using phylogenetic analyses. Both studies found that the first cases came from China and Europe since S and G variants of SARS-CoV-2 were detected. In the case of Italy, a reentry from Germany was detected (Giovanetti *et al.*, 2020a). Tracing of imported cases to other Latin American countries has also been performed using strategies such as data recovery of international flights from the most affected countries to Brazil (Candido *et al.*, 2020), or recompilation of epidemiological data from hospitals in Bolivia (Escalera-Antezana *et al.*, 2020). Both studies concluded that the first imported cases came from Europe, specifically from Italy and Spain. Moreover, other bioinformatics tools have been used to contribute to epidemiological



understanding. For example, a Bayesian phylogeographic reconstruction suggested that Wuhan was effectively the outbreak epicenter on November 25, 2019, spreading later to other Chinese regions (Benvenuto *et al.*, 2020c).

Additionally, the geo-positioning of some cases and the heterogeneity of the outbreak progress among countries, with demographic similarities, have been reported (de Figueiredo *et al.*, 2020; Xu *et al.*, 2020). Other epidemiological studies have been done to predict the COVID-19 spreading (Benvenuto *et al.*, 2020d; Córdova-Lepe *et al.*, 2020; González-Jaramillo *et al.*, 2020; Manrique-Abril *et al.*, 2020), which concluded that containment strategies are required to avoid overspreading in countries like Chile and Colombia. Similarly, Kraemer *et al.* (2020) analyzed the effect of mobility in China before and after the sanitary containment of Wuhan in the COVID-19 spreading in this country; they demonstrated that decreasing mobility favors the reduction of COVID-19 spreading.

5.2. Meta-analyses performed

Latin American researchers have also published meta-analyses of clinical, laboratory, and image data from reported COVID-19 cases (Borges do Nascimento *et al.*, 2020; Rodriguez-Morales *et al.*, 2020b). On the one hand, the meta-analysis submitted by Rodriguez-Morales *et al.* (2020b) on February 29, 2020, used 19 articles with 2,874 patients for quantitative analyses. On the other hand, the meta-analysis of Borges do Nascimento *et al.* (2020), submitted six days later, employed 61 studies with 59,254 patients. Both revisions included the most common symptoms as well as typical abnormalities observed in chest radiographs and computed tomographies, which were like other respiratory illnesses and viral pneumonia, making it difficult to distinguish from them (Borges do Nascimento *et al.*, 2020). Oxygen support in critical patients was also



analyzed, where Borges do Nascimento *et al.* (2020) suggested that excluding the non-invasive ventilation usage since no evidence supports its benefits.

Regarding lethality, the most affected population (81%) was the older group (60 years or more), but additional information is required to understand the COVID-19 impact on other continents because most of the data used in these meta-analyses came from China. Therefore, meta-analyses using Latin American cases would also be ideal for determining how COVID-19 could affect this region, which has some differences, such as lower average age or higher exposure to respiratory infections than other regions like Europe (Amariles *et al.*, 2020a). A third meta-analysis was found, which suggested that it could be possible to predict if a patient with COVID-19 can present complications. Lagunas-Rangel (2020) hypothesized that complications are related to high levels of neutrophil-to-lymphocyte ratio (NLR) and low levels of lymphocyte-to-C-reactive protein ratio (LCR).

5.3. Search for potential treatments

Concerning treatments to respiratory issues, Khoury *et al.* (2020) revised respiratory therapies for COVID-19 patients using cell-based treatments such as mesenchymal stem cells (MSCs), derivatives, or other cells, which have shown positive results in pre-clinical models of influenza. Conversely, they argued that there were few coronavirus studies, such as the case of seven COVID-19 patients in Beijing treated with MSCs, who showed apparent improvements up to 4 days after treatment, but lacked detailed information (Leng *et al.*, 2020). Therefore, after a systematic search in databases, Khoury *et al.* (2020) found 27 ongoing treatments with 1,287 patients. The authors also highlighted the importance of following ethical protocols for these types of treatments.



267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

Besides the previously mentioned review, since currently there are no approved treatments or vaccines for COVID-19, other revisions have summarized the development of clinical trials for COVID-19 treatments. This is the case of the search made by Rosa & Santos (2020), who looked for ongoing clinical trials in Clinicaltrials.gov. The authors used some constraints in their search, such as low cost, reduced time to reach markets, existing pharmaceutical supplies, or the possibility to combine with other drugs. In total, 24 clinical trials were found, most of them in clinical phases 2, 3, or 4, with a scheduled end in 2020. These ongoing clinical trials are using chloroquine, hydroxychloroquine, human immunoglobulin, remdesivir, arbidol, lopinavir, ritonavir, oseltamivir, darunavir, cobicistat, interferons, carrimycin, danoprevir, xiyanping, favipiravir, thalidomide, vitamin C, methylprednisolone, pirfenidone, bromhexie, bevacizumab, fingolimod, and traditional Chinese medicines (TCM). Similarly, Serafin et al. (2020) searched for new treatments for coronaviruses like SARS-CoV. SARS-CoV-2, and HCoV-OC43 in PubMed, SCOPUS, and Web of Science databases. The drugs found as SARS-CoV-2 treatments are captopril, chloroquine, clomipramine, disulfiram, enalapril, hydroxychloroquine, mefloquine, metformin, nitazoxanide, remdesivir, and teicoplanin. This review highlighted positive results using chloroquine, hydroxychloroquine, teicoplanin, and hydroxychloroguine in conjunction with azithromycin. Finally, Rosales-Mendoza (2020) suggested that a potential treatment with biotechnological origin could be produced using plant species as hosts.

285

286

287

288

5.4. Medical considerations

Most medical articles studied populations at risk and comorbidities, also provided recommendations and guidelines for medical personnel. Rascado Sedes *et al.* (2020) developed a



289	contingency plan that allows an optimal response of the intensive care units (ICU) to the
290	pandemic. The plan considers possible scenarios, the need for human and technical resources,
291	communication and information, optimized use of resources, and personal protective equipment
292	(PPE).
293	Healthcare workers, emergency room physicians, anesthesiologists, dentists, ophthalmologists,
294	head and neck surgeons, maxillofacial surgeons, and otolaryngologists are among the most
295	vulnerable ones because they perform procedures that can aerosolize secretions (Kowalski et al.,
296	2020). According to several studies, articles, and protocols, Boccalatte et al. (2020) summarized
297	recommendations related to PPE, mandatory use of protective suits, head covers, eye protection,
298	mask, gloves, and N95, FFP2, or PAPR masks, personnel training, and techniques or
299	manoeuvers for different medical practices.
300	Concerning surgeries, although there is no information about to translate risks to the operating
301	room team during such procedures to COVID-19 patients, the recommendation is to postpone
302	them (Cohen et al., 2020; Ducournau et al., 2020). The situations in which a delay in the surgical
303	procedure may affect the patient, such as some oncologic or organ transplant surgeries, surgery
304	must be performed following strict preventive measures. In the case of unpostponable abdominal
305	surgeries, a laparotomic operation with regional anesthesia should be preferred (Carneiro et al.,
306	2020; Cohen et al., 2020; Correia et al., 2020; Quintão et al., 2020). Other articles summarized
307	protocols and recommendations for hand (Ducournau et al., 2020), head and neck (Kowalski et
308	al., 2020), and urologic surgeries (Puliatti et al., 2020).
309	Researchers have also performed literature reviews concerning populations with higher risk due
310	to comorbidities. First, Hussain et al. (2020) focused on patients with diabetes mellitus and
311	COVID-19. They summarized the different determinants that associate this pathology with



greater severity and death, as well as the importance of multidisciplinary medical management.
The authors mentioned that COVID-19 could cause pancreatic damage, which could affect
patients with diabetes. Likewise, the positive effects of hydroxychloroquine and chloroquine on
diabetic patients were mentioned, such as reducing insulin degradation tending to normalize
glucose levels. Therefore, in case hydroxychloroquine or chloroquine is administered,
antidiabetic drug doses should be readjusted to avoid hypoglycemic events. The authors also
mentioned the necessity to continue studying in these patients the chronic inflammation, immune
response, coagulation activity, and vascular permeability, as well as whether hyperglycemia or
hypoglycemia can alter the virulence of SARS-CoV-2, or whether the virus itself interferes with
insulin secretion or glycemic control. All this information will be needed to propose adequate
clinical treatments.
Likewise, Puliatti et al. (2020) considered the effect of SARS-CoV-2 in different organs of the
urinary tract. They highlighted that ACE2-positive cells (target of SARS-CoV-2 spike proteins)
have been found in these organs, which could have a high risk of affectation, even leading to
death, which explains the kidney damage experimented in some COVID-19 patients. Similarly,
chronic hemodialysis patients are also at particular risk due to their immunosuppression status,
advanced age, and comorbidities coexistence. Vega-Vega et al. (2020) summarized the
recommendations for these patients proposed by three international organizations: Center for
Disease Control and Prevention (CDC), the Spanish Society of Nephrology, and the Latin
American Society of Nephrology and Hypertension, to which were added suggestions of some
experts. Some recommendations are the proper definition of cases, guidelines for patients and
family, scrutiny of suspicious COVID-19 cases and their management within hemodialysis units
PPE employment, and sanitation of surfaces and devices.



Another group at risk mentioned by researchers is related to critical COVID-19 patients who need assisted ventilation. Some authors recommend taking into account some considerations before using high-flow nasal oxygen therapy, non-invasive ventilation, or extracorporeal membrane oxygenation (ECMO), the latter being a treatment that no all medical centers can afford. First, if the medical center has adequate protection levels for health workers from exhaled air dispersed, and second, the impact of treatment on acute respiratory distress syndrome (ARDS) (Bartlett *et al.*, 2020; Ñamendys-Silva, 2020a; Ñamendys-Silva, 2020b). Similarly, Chica-Meza *et al.* (2020) summarized conventional and non-conventional respiratory therapies in critical COVID-19 patients, including recommendations and considerations. Finally, surveys have been performed to identify COVID-19 impacts in patients at risk, such as pediatric patients with cancer (Hrusak *et al.*, 2020), but the information is still limited; however, the recommendation is to follow the same medical practices described previously.

5.5. Mental health considerations

Mental health care must be considered, given that quarantine can cause boredom, loneliness, anger, anxiety, depression, and stress. Patients and health workers should have mental health services (Carvalho *et al.*, 2020b; Lima *et al.*, 2020). In especial when more people can be affected by mental issues during the outbreak than by the outbreak itself (Ornell *et al.*, 2020), and previous outbreaks have caused post-traumatic stress disorder (PTSD) in health workers (Torales *et al.*, 2020).

Concerning performed studies on mental issues, first, Fonseca *et al.* (2020) established recommendations for patients with schizophrenia. Among recommendations are an adequate identification of COVID-19 symptoms, prevention of worsening of psychiatric symptoms,



relapses due to the closed environment, fear of disease and isolation, use of telemedicine, promoting adherence to antipsychotic medication regimens, reducing emotional distress, hygiene practices, and family support. Finally, Carvalho *et al.* (2020a), using questionnaires to Brazilians, investigated whether extroverted and conscientious people are engaged with the containment measures implemented during the COVID-19 pandemic. They found that extroverted people seem to lack commitment to containment measures, while people with conscientiousness personality tend to follow recommendations. Therefore, at least in Brazil, strategies for extroverted people should be proposed to avoid they become transmission vectors. However, the idiosyncrasy is similar throughout Latin America; thus, these strategies should be required in the entire region.

6. Additional Concerns

6.1. Social and environmental concerns

- Telemedicine should be considered as an alternative to patient attention to avoid COVID-19 spreading. However, this strategy is limited because of the scarce existence of telemedicine systems; thus, social media could be used (Assis Machado *et al.*, 2020; Quintão *et al.*, 2020).
- Elachola *et al.* (2020) highlighted that there are no prevalence and effectiveness studies on using facemasks related to the COVID-19 outbreak. This information could be useful in providing recommendations about their usage. However, based on past outbreaks, the evidence did not show positive or negative effects when the population used facemasks (Stern *et al.*, 2020).
- Since the first COVID-19 cases reported in Latin America, fake news and misinformation
 have increased, where even treatments with potential health affectations have been proposed,



381		as in the case of using chloroform or ether as alleged COVID-19 treatments (Lana et al.,
382		2020; Martins & Santos, 2020). Additionally, information should be verified, avoiding panic
383		spreading, which has caused panic buying of supplies and medications (Cuan-Baltazar et al.,
384		2020).
385	•	The quick COVID-19 spreading in different regions and countries could cause that health
386		workers to become overwhelmed, therefore training new personal, although challenging, is a
387		necessity that could help to attend the current outbreak. Additionally, the pharmacy
388		workforce should be prepared as they are the first ones to attend possible cases of infection
389		(Amariles et al., 2020b; Aruru et al., 2020; Haines et al., 2020).
390	•	Countries with low or middle incomes, such as Latin American countries, may have already
391		saturated their health systems. Hence, the COVID-19 outbreak could oversaturate them
392		(Carneiro et al., 2020), which can be exacerbated by the lack of government preparation and
393		social policies, such as the Ecuadorian case (Hallo et al., 2020).
394	•	Based on events that occurred with the "Diamond Princess" cruise, alternatives should be
395		proposed to quarantine people from other cruises and illegal immigrants entering a country
396		(Sawano et al., 2020).
397	•	Due to the current outbreak, many activities have been interrupted, which joined the
398		socioeconomic limitations of vulnerable groups, could lead to food insecurity in these
399		populations, who even have no access to clean water (Oliveira et al., 2020).
100	•	Knowing that COVID-19 has a zoonotic origin, One Health approach has taken relevance,
101		which seeks integrative studies where the health of humans, environment, and animals are
102		considered to understand the virus environment, allowing the prevention or mitigation of
103		future outbreaks (Bonilla-Aldana <i>et al.</i> , 2020a).



	oncerns

406	•	Initial reports of some pathologies such as rheumatic diseases or neuromyelitis optica
407		spectrum disorder (NMOSD) have shown that they do not increase the risk of complications
408		like other comorbidities. However, further studies are needed (Carnero Contentti & Correa,
409		2020; Figueroa-Parra <i>et al.</i> , 2020).
410	•	Angiotensin II receptor blockers (ATII-RB) are hypertensive drugs that increase ACE2
411		expression; therefore, there is a possibility that they can favor the internalization of SARS-
412		CoV-2 within the cell; thus, further studies are required. However, suspending ATII-RB
413		therapy may cause even higher affectations than COVID-19 itself; the risk-benefit ratio
414		should be evaluated. In case doctors consider suspending it, there are other options like
415		thiazide diuretics drugs (Gracia-Ramos, 2020; Marin, 2020).
416	•	As previously mentioned, chloroquine and hydroxychloroquine are in vitro inhibitors of
417		SARS-CoV-2 infection. However, concerns are focused on whether these medications could
418		decrease viral load or prevent infection, clinical disease, clinical severity, or even death.
419		Other factors, such as side effects, should also be considered (Kim et al., 2020; Monteiro et
420		al., 2020; Picot et al., 2020).
421	•	COVID-19 mainly affects the respiratory system, but it can also alter the central nervous
422		system. Hence, possible affectations in the respiratory center could exacerbate respiratory
423		distress caused by pulmonary affectation (Conde et al., 2020).
424	•	Tropical countries affected by dengue could face two outbreaks at the same time, dengue and
425		COVID-19, which could affect the population, even coinfecting some patients
426		simultaneously. Both outbreaks will require the intensive attention of health systems to avoid





127	a crossed affectation between them, which can be challenging and overwhelming for the
128	health systems (Lorenz et al., 2020; Navarro et al., 2020; Rodriguez-Morales et al., 2020c;
129	Saavedra-Velasco et al., 2020).
130	• As SARS-CoV-2 can remain in saliva, oral health professionals require research focused on
131	the influence of COVID-19 in their activities to take appropriate measures. However, the
132	recommendation is to stop dental treatments (Martelli-Júnior et al., 2020; Napimoga &
133	Freitas, 2020; Sabino-Silva et al., 2020).
134	• Strategies during intubation are not the only important ones to avoid COVID-19 spreading in
135	health workers during medical procedures; strategies for extubation are also required
136	(Trujillo, 2020).
137	• There is no evidence that immunosuppressant treatments (ITS) could decrease or increase the
138	risk of severe COVID-19 infection; therefore, further investigation is recommended. In case
139	treatments are suspended, factors such as potential issues on patients should be considered
140	(Carnero Contentti & Correa, 2020).
141	• There is limited evidence of COVID-19 effect on pregnant women; hence, cases of pregnant
142	women with COVID-19 should be studied to understand the clinical impact of the infection
143	(Zambrano <i>et al.</i> , 2020).
144	
145	Conclusions
+43	Conclusions
146	Although our purpose was to give visibility to the contribution of Latin American researchers in
147	the knowledge generation related to the COVID-19 outbreak, this review has two drawbacks.
148	The first is the continuous availability of new publications; therefore, an observation window

was employed. Second, several Latin American researchers are currently working on other



continents without a Latin American affiliation, making them impossible to track. However, after this literature review, we were able to evidence the active participation of Latin American researchers in different subjects, whether as members of national, regional (LANCOVID-19), or even international research groups. Concerning our findings, the publications evidenced that these research groups have advanced in molecular and medical subjects, mainly in genetic understanding, epidemiological behaviors, meta-analyses, interaction between COVID-19 and other pathologies, and recommendations to medical procedures. Finally, understanding that this health crisis requires the commitment of as many researchers as possible, our wish is that the contribution of Latin American researchers continues to grow. Some topics with regional and global interest for future studies include *in silico* analyses of potential treatments and their respective *in vitro* and *in vivo* validations, meta-analysis of Latin American patients, and epidemiological surveillances. Regarding medical considerations, a deeper understanding of the COVID-19 interaction with risk comorbidities is needed to propose adequate clinical treatments. The same applies to unexplored/underexplored physical and mental pathologies, such as dengue.

Acknowledgments

This review is in memory of all deceased by the COVID-19 outbreak.

References

Amariles P, Granados J, Ceballos M, and Montoya CJ. 2020a. COVID-19 in Colombia endpoints. Are we different, like Europe? *Research in Social and Administrative Pharmacy*. DOI 10.1016/j.sapharm.2020.03.013.



472	Amariles P, Ledezma-Morales M, Salazar-Ospina A, and Hincapié-García JA. 2020b. How to
473	link patients with suspicious COVID-19 to health system from the community
474	pharmacies? A route proposal. Research in Social and Administrative Pharmacy. DOI
475	10.1016/j.sapharm.2020.03.007.
476	Andersen KG, Rambaut A, Lipkin WI, Holmes EC, and Garry RF. 2020. The proximal origin of
477	SARS-CoV-2. Nature Medicine. DOI 10.1038/s41591-020-0820-9.
478	Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, and Ciccozzi M. 2020.
479	COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. Journal of Medical
480	Virology. DOI 10.1002/jmv.25719.
481	Aruru M, Truong H-A, and Clark S. 2020. Pharmacy Emergency Preparedness and Response
482	(PEPR) framework for expanding pharmacy professionals' roles and contributions to
483	emergency preparedness and response during the COVID-19 pandemic and beyond.
484	Research in Social and Administrative Pharmacy. DOI 10.1016/j.sapharm.2020.04.002.
485	Assis Machado R, Lins de Souza N, Maria Oliveira R, Martelli Júnior H, and Rogério Ferreti
486	Bonan P. 2020. Social Media and telemedicine for oral diagnosis and counselling in the
487	COVID-19 Era. <i>Oral Oncology</i> :104685. DOI 10.1016/j.oraloncology.2020.104685.
488	Bartlett RH, Ogino MT, Brodie D, McMullan DM, Lorusso R, MacLaren G, Stead CM, Rycus P,
489	Fraser JF, Belohlavek J, Salazar L, Mehta Y, Raman L, and Paden ML. 2020. Initial
490	ELSO Guidance Document: ECMO for COVID-19 Patients with Severe
491	Cardiopulmonary Failure. ASAIO Journal: Artificial Organ Research and Development
492	Online First. DOI 10.1097/mat.00000000001173.
493	Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, Ciccozzi M, and
494	Cassone A. 2020a. Evolutionary analysis of SARS-CoV-2: how mutation of Non-



495	Structural Protein 6 (NSP6) could affect viral autophagy. Journal of Infection. DOI
496	10.1016/j.jinf.2020.03.058.
497	Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, and Ciccozzi M. 2020b. The
498	2019-new coronavirus epidemic: Evidence for virus evolution. Journal of Medical
499	Virology 92:455-459. DOI 10.1002/jmv.25688.
500	Benvenuto D, Giovanetti M, Salemi M, Prosperi M, De Flora C, Alcantara LC, Angeletti S, and
501	Ciccozzi M. 2020c. The global spread of 2019-nCoV: a molecular evolutionary analysis.
502	Pathogens and Global Health. DOI 10.1080/20477724.2020.1725339.
503	Benvenuto D, Giovanetti M, Vassallo L, Angeletti S, and Ciccozzi M. 2020d. Application of the
504	ARIMA model on the COVID-2019 epidemic dataset. Data in Brief 29. DOI
505	10.1016/j.dib.2020.105340.
506	Boccalatte LA, Larrañaga JJ, Perez Raffo GM, Teijido CA, García Fornari G, Staneloni MI, and
507	Figari MF. 2020. Brief guideline for the prevention of COVID-19 infection in head and
508	neck and otolaryngology surgeons. American Journal of Otolaryngology: 102484. DOI
509	10.1016/j.amjoto.2020.102484.
510	Bonilla-Aldana DK, Dhama K, and Rodriguez-Morales AJ. 2020a. Revisiting the One Health
511	Approach in the Context of COVID-19: A Look into the Ecology of this Emerging
512	Disease. Advances in Animal and Veterinary Sciences 8:234-236. DOI
513	10.17582/journal.aavs/2020/8.3.234.236.
514	Bonilla-Aldana DK, Quintero-Rada K, Montoya-Posada JP, Ramirez-Ocampo S, Paniz-Mondolfi
515	A, Rabaan AA, Sah R, and Rodriguez-Morales AJ. 2020b. SARS-CoV, MERS-CoV and
516	now the 2019-novel CoV: Have we investigated enough about coronaviruses? - A



517	bibliometric analysis. Travel Medicine and Infectious Disease 33. DOI
518	10.1016/j.tmaid.2020.101566.
519	Borges do Nascimento JI, Cacic N, Abdulazeem MH, von Groote CT, Jayarajah U, Weerasekara
520	I, Esfahani AM, Civile TV, Marusic A, Jeroncic A, Carvas Junior N, Pericic PT,
521	Zakarija-Grkovic I, Meirelles Guimarães MS, Luigi Bragazzi N, Bjorklund M, Sofi-
522	Mahmudi A, Altujjar M, Tian M, Arcani MD, O'Mathúna PD, and Marcolino SM. 2020.
523	Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-
524	Analysis. Journal of Clinical Medicine 9. DOI 10.3390/jcm9040941.
525	Candido DDS, Watts A, Abade L, Kraemer MUG, Pybus OG, Croda J, Oliveira W, Khan K,
526	Sabino EC, and Faria NR. 2020. Routes for COVID-19 importation in Brazil. Journal of
527	travel medicine. DOI 10.1093/jtm/taaa042.
528	Cardenas-Conejo Y, Linan-Rico A, Garcia-Rodriguez DA, Centeno-Leija S, and Serrano-Posada
529	H. 2020. An exclusive 42 amino acid signature in pp1ab protein provides insights into the
530	evolutive history of the 2019 novel human-pathogenic coronavirus (SARS-CoV-2).
531	Journal of Medical Virology. DOI 10.1002/jmv.25758.
532	Carneiro A, Wrocławski M, Nahar B, Soares A, Cardoso A, Kim N, and Carvalho F. 2020.
533	Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a
534	management guideline proposal for low- and middle-income countries during the crisis
535	period. International Brazilian Journal of Urology 46. DOI 10.1590/S1677-
536	5538.IBJU.2020.04.03.
537	Carnero Contentti E, and Correa J. 2020. Immunosuppression during the COVID-19 pandemic in
538	neuromyelitis optica spectrum disorders patients: A new challenge. Multiple Sclerosis
539	and Related Disorders 41:102097. DOI 10.1016/j.msard.2020.102097.



540	Carvalho LdF, Pianowski G, and Gonçalves AP. 2020a. Personality differences and COVID-19:
541	are extroversion and conscientiousness personality traits associated with engagement
542	with containment measures? Trends in Psychiatry and Psychotherapy. DOI
543	10.1590/2237-6089-2020-0029.
544	Carvalho PMdM, Moreira MM, de Oliveira MNA, Landim JMM, and Neto MLR. 2020b. The
545	psychiatric impact of the novel coronavirus outbreak. Psychiatry Research 286:112902.
546	DOI 10.1016/j.psychres.2020.112902.
547	Castillo AE, Parra B, Tapia P, Acevedo A, Lagos J, Andrade W, Arata L, Leal G, Barra G,
548	Tambley C, Tognarelli J, Bustos P, Ulloa S, Fasce R, and Fernández J. 2020.
549	Phylogenetic analysis of the first four SARS-CoV-2 cases in Chile. Journal of Medical
550	Virology n/a. DOI 10.1002/jmv.25797.
551	Ciccozzi M, Benvenuto D, Giovanetti M, Bianchi M, Pascarella S, and Angeletti S. 2020.
552	Response to Ribeiro da Silva et al., "Role of Nonstructural Proteins in the Pathogenesis of
553	SARS-CoV-2. Journal of Medical Virology n/a. DOI 10.1002/jmv.25863.
554	Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, Sagnelli C, Bianchi
555	M, Bernardini S, and Ciccozzi M. 2020. COVID-19 Outbreak: An Overview.
556	Chemotherapy. DOI 10.1159/000507423.
557	Cleemput S, Dumon W, Fonseca V, Karim WA, Giovanetti M, Alcantara LC, Deforche K, and
558	de Oliveira T. 2020. Genome Detective Coronavirus Typing Tool for rapid identification
559	and characterization of novel coronavirus genomes. Bioinformatics. DOI
560	10.1093/bioinformatics/btaa145.



561	Cohen SL, Liu G, Abrao M, Smart N, and Heniford 1. 2020. Perspectives on Surgery in the time
562	of COVID-19: Safety First. Journal of Minimally Invasive Gynecology. DOI
563	10.1016/j.jmig.2020.04.003.
564	Conde G, Quintana Pájaro LD, Quintero Marzola ID, Villegas YR, and Moscote Salazar LR.
565	2020. Neurotropism of SARS-CoV 2: Mechanisms and manifestations. Journal of the
566	Neurological Sciences:116824. DOI 10.1016/j.jns.2020.116824.
567	Córdova-Lepe F, Gutiérrez-Aguilar R, and Gutiérrez-Jara JP. 2020. Number of COVID-19 cases
568	in Chile at 120 days with data at 21/03/2020 and threshold of daily effort to flatten the
569	epi-curve. Medwave 20:e7861. DOI 10.5867/medwave.2020.02.7861.
570	Correia MITD, Ramos RF, and Bahten LCV. 2020. Os cirurgiões e a pandemia do COVID-19.
571	Revista do Colégio Brasileiro de Cirurgiões 47. DOI 10.1590/0100-6991e-20202536.
572	Cuan-Baltazar JY, Muñoz-Perez MJ, Robledo-Vega C, Pérez-Zepeda MF, and Soto-Vega E.
573	2020. Misinformation of COVID-19 on the Internet: Infodemiology Study. JMIR Public
574	Health Surveill 6:e18444. DOI 10.2196/18444.
575	Cupertino MC, Resende MB, Mayers NAJ, Carvalho LM, and Siqueira-Batista R. 2020.
576	Emerging and re-emerging human infectious diseases: A systematic review of the role of
577	wild animals with a focus on public health impact. Asian Pacific Journal of Tropical
578	Medicine 13:99-106. DOI 10.4103/1995-7645.277535.
579	Chica-Meza C, Peña-López LA, Villamarín-Guerrero HF, Moreno-Collazos JE, Rodríguez-
580	Corredor LC, Lozano WM, and Vargas-Ordoñez MP. 2020. Cuidado Respiratorio En
581	Covid-19. Acta Colombiana de Cuidado Intensivo. DOI 10.1016/j.acci.2020.04.001.



582	de Figueiredo AM, Codina AD, de Figueiredo DCMM, Gil-García E, and Kalache A. 2020.
583	Letalidad del COVID-19: ausencia de patrón epidemiológico. Gaceta Sanitaria. DOI
584	10.1016/j.gaceta.2020.04.001.
585	Diaz-Quijano FA, Rodriguez-Morales AJ, and Waldman EA. 2020. Translating transmissibility
586	measures into recommendations for coronavirus prevention. Revista de Saúde Pública 54
587	DOI 10.11606/s1518-8787.2020054002471.
588	Ducournau F, Arianni M, Awwad S, Baur EM, Beaulieu JY, Bouloudhnine M, Caloia M, Chagar
589	K, Chen Z, Chin AY, Chow EC, Cobb T, David Y, Delgado PJ, Woon Man Fok M,
590	French R, Golubev I, Haugstvedt JR, Ichihara E, Jorquera RA, Koo SCJJ, Lee JY, Lee
591	YK, Lee YJ, Liu B, Kaleli T, Mantovani GR, Mathoulin C, Messina JC, Muccioli C,
592	Nazerani S, Ng CY, Obdeijn MC, Van Overstraeten L, Prasetyono TOH, Ross M, Shih
593	JT, Smith N, Suarez RFA, Chan PT, Tiemdjo H, Wahegaonkar A, Wells MC, Wong WY
594	Wu F, Yang XF, Yanni D, Yao J, and Liverneaux PA. 2020. COVID-19: Initial
595	experience of an international group of hand surgeons. Hand Surgery and Rehabilitation.
596	DOI 10.1016/j.hansur.2020.04.001.
597	Elachola H, Ebrahim SH, and Gozzer E. 2020. COVID-19: Facemask use prevalence in
598	international airports in Asia, Europe and the Americas, March 2020. Travel Medicine
599	and Infectious Disease:101637. DOI 10.1016/j.tmaid.2020.101637.
600	Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, Alarcón-De-la-Vega G,
601	Alvarado-Arnez LE, Balderrama-Saavedra MA, Bonilla-Aldana DK, and Rodríguez-
602	Morales AJ. 2020. Clinical features of cases and a cluster of Coronavirus Disease 2019
603	(COVID-19) in Bolivia imported from Italy and Spain. Travel Medicine and Infectious
604	Disease:101653. DOI 10.1016/j.tmaid.2020.101653.



605	Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, and Galarza-
606	Delgado DA. 2020. Are my patients with rheumatic diseases at higher risk of COVID-
607	19? Annals of the Rheumatic Diseases. DOI 10.1136/annrheumdis-2020-217322.
608	Fonseca L, Diniz E, Mendonça G, Malinowski F, Mari J, and Gadelha A. 2020. Schizophrenia
609	and COVID-19: risks and recommendations. Brazilian Journal of Psychiatry. DOI
610	10.1590/1516-4446-2020-0010.
611	Giovanetti M, Angeletti S, Benvenuto D, and Ciccozzi M. 2020a. A doubt of multiple
612	introduction of SARS-CoV-2 in Italy: A preliminary overview. Journal of Medical
613	Virology. DOI 10.1002/jmv.25773.
614	Giovanetti M, Benvenuto D, Angeletti S, and Ciccozzi M. 2020b. The first two cases of 2019-
615	nCoV in Italy: Where they come from? Journal of Medical Virology 92:518-521. DOI
616	10.1002/jmv.25699.
617	González-Jaramillo V, González-Jaramillo N, Gómez-Restrepo C, Palacio-Acosta CA, Gómez-
618	López A, and Franco OH. 2020. Proyecciones de impacto de la pandemia COVID-19 en
619	la población colombiana, según medidas de mitigación. Datos preliminares de modelos
620	epidemiológicos para el periodo del 18 de marzo al 18 de abril de 2020. Revista de Salua
621	Pública 22. DOI 10.15446/rsap.v22.85789.
622	Gracia-Ramos AE. 2020. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?
623	Archives of Medical Research. DOI 10.1016/j.arcmed.2020.03.011.
624	Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,
625	and Neher RA. 2018. NextStrain: Real-time tracking of pathogen evolution.
626	Bioinformatics 34:4121-4123. DOI 10.1093/bioinformatics/bty407.



627	Haines A, de Barros EF, Berlin A, Heymann DL, and Harris MJ. 2020. National UK programme
628	of community health workers for COVID-19 response. The Lancet 395:1173-1175. DOI
629	10.1016/S0140-6736(20)30735-2.
630	Hallo A, Rojas A, and Hallo C. 2020. Perspective from Ecuador, the Second Country with More
631	Confirmed Cases of Coronavirus Disease 2019 in South America: A Review. Cureus 12.
632	DOI 10.7759/cureus.7452.
633	Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, Rives S, del Pozo Carlavilla M,
634	Valerio Alonso ME, Domínguez Pinilla N, Bourquin J-P, Schmiegelow K, Attarbaschi A,
635	Grillner P, Mellgren K, Ten Bosch van der Werff J, Pieters R, Brozou T, Borkhardt A,
636	Escherich G, Lauten M, Stanulla M, Smith O, Juh Yeoh AE, Elitzur S, Vora A, Li C-K,
637	Ariffin H, Kolenova A, Dallapozza L, Farah R, Lazic J, Manabe A, Styczynski J, Kovacs
638	G, Ottoffy G, Felice M, Buldini B, Conter V, Stary J, and Schrappe M. 2020. Flash
639	Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment.
640	European Journal of Cancer. DOI 10.1016/j.ejca.2020.03.021.
641	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T,
642	Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang
643	G, Jiang R, Gao Z, Jin Q, Wang J, and Cao B. 2020. Clinical features of patients infected
644	with 2019 novel coronavirus in Wuhan, China. The Lancet 395:497-506. DOI
645	10.1016/s0140-6736(20)30183-5.
646	Hussain A, Bhowmik B, and do Vale Moreira NC. 2020. COVID-19 and Diabetes: Knowledge
647	in Progress. Diabetes Research and Clinical Practice:108142. DOI
648	10.1016/j.diabres.2020.108142.



649	Johns Hopkins University. 2020. COVID-19 Dashboard by the Center for Systems Science and
650	Engineering (CSSE). Available at https://coronavirus.jhu.edu/map.html.
651	Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, and Weiss DJ. 2020. Current Status of
652	Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19.
653	European Respiratory Journal:2000858. DOI 10.1183/13993003.00858-2020.
654	Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, Graef ER, Korster
655	P, Sattui SE, Sirotich E, Ugarte-Gil MF, Webb K, Grainger R, and Alliance† C-GR.
656	2020. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its
657	Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Annals of
658	internal medicine:M20-1223. DOI 10.7326/m20-1223.
659	Kowalski LP, Sanabria A, Ridge JA, Ng WT, de Bree R, Rinaldo A, Takes RP, Mäkitie AA,
660	Carvalho AL, Bradford CR, Paleri V, Hartl DM, Poorten VV, Nixon IJ, Piazza C, Lacy
661	P, Rodrigo JP, Guntinas-Lichius O, Mendenhall WM, D'Cruz A, Lee AWM, and Ferlito
662	A. 2020. COVID-19 pandemic: effects and evidence-based recommendations for
663	otolaryngology and head and neck surgery practice. Head & Neck n/a. DOI
664	10.1002/hed.26164.
665	Kraemer MUG, Yang C-H, Gutierrez B, Wu C-H, Klein B, Pigott DM, du Plessis L, Faria NR,
666	Li R, Hanage WP, Brownstein JS, Layan M, Vespignani A, Tian H, Dye C, Pybus OG,
667	and Scarpino SV. 2020. The effect of human mobility and control measures on the
668	COVID-19 epidemic in China. Science:eabb4218. DOI 10.1126/science.abb4218.
669	Lagunas-Rangel FA. 2020. Neutrophil-to-Lymphocyte ratio and Lymphocyte-to-C-reactive
670	protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-
671	analysis. Journal of Medical Virology n/a. DOI 10.1002/jmv.25819.



672	Lana RM, Coelho FC, Gomes MFDC, Cruz OG, Bastos LS, Villela DAM, and Codeço CT.
673	2020. The novel coronavirus (SARS-CoV-2) emergency and the role of timely and
674	effective national health surveillance. Cadernos de saude publica 36:e00019620. DOI
675	10.1590/0102-311x00019620.
676	Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang
677	W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao
678	Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A,
679	Chakrabarti S, Min K-J, Ellison-Hughes G, Caruso C, Jin K, and Zhao RC. 2020.
680	Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients
681	with COVID-19 Pneumonia. Aging and Disease 11:216-228. DOI
682	10.14336/ad.2020.0228.
683	Lima CKT, Carvalho PMDM, Lima IDAAS, Nunes JVADO, Saraiva JS, de Souza RI, da Silva
684	CGL, and Neto MLR. 2020. The emotional impact of Coronavirus 2019-nCoV (new
685	Coronavirus disease). Psychiatry Research 287. DOI 10.1016/j.psychres.2020.112915.
686	Lorenz C, Azevedo TS, and Chiaravalloti-Neto F. 2020. COVID-19 and dengue fever: A
687	dangerous combination for the health system in Brazil. Travel Medicine and Infectious
688	Disease: 101659. DOI 10.1016/j.tmaid.2020.101659.
689	Manrique-Abril FG, Agudelo-Calderon CA, González-Chordá VM, Gutiérrez-Lesmes O, Téllez-
690	Piñerez CF, and Herrera-Amaya G. 2020. Modelo SIR de la pandemia de COVID-19 en
691	Colombia. Revista de Salud Pública 22. DOI 10.15446/rsap.v22.85977.
692	Marin GH. 2020. Facts and reflections on COVID-19 and anti-hypertensives drugs. <i>Drug</i>
693	Discoveries & Therapeutics. DOI 10.5582/ddt.2020.01017.



694	Martelli-Júnior H, Machado RA, Martelli DRB, and Coletta RD. 2020. Dental journals and
695	coronavirus disease (COVID-19): A current view. Oral Oncology:104664. DOI
696	10.1016/j.oraloncology.2020.104664.
697	Martins PR, and Santos VS. 2020. No evidence supports the use of ether and chloroform
698	inhalation for treating COVID-19. Revista Panamericana De Salud Publica-Pan
699	American Journal of Public Health 44. DOI 10.26633/rpsp.2020.41.
700	Millán-Oñate J, Rodriguez-Morales AJ, Camacho-Moreno G, Mendoza-Ramírez H, Rodríguez-
701	Sabogal IA, and Álvarez-Moreno C. 2020. A NEW EMERGING ZOONOTIC VIRUS
702	OF CONCERN: THE 2019 NOVEL CORONAVIRUS (COVID-19). Infectio 24. DOI
703	10.22354/in.v24i3.848.
704	Monteiro WM, Brito-Sousa JD, Baía-da-Silva D, Melo GCd, Siqueira AM, Val F, Daniel-
705	Ribeiro CT, and Guimarães Lacerda MV. 2020. Driving forces for COVID-19 clinical
706	trials using chloroquine: the need to choose the right research questions and outcomes.
707	Revista da Sociedade Brasileira de Medicina Tropical 53. DOI 10.1590/0037-8682-
708	0155-2020.
709	Napimoga MH, and Freitas ARRd. 2020. Dentistry vs Severe Acute Respiratory Syndrome
710	Coronavirus 2: How to face this enemy. RGO - Revista Gaúcha de Odontologia 68. DOI
711	10.1590/1981-863720200001120200034.
712	Navarro J-C, Arrivillaga-Henríquez J, Salazar-Loor J, and Rodriguez-Morales AJ. 2020.
713	COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America:
714	Pushing strained health care systems over the edge. Travel Medicine and Infectious
715	Disease:101656. DOI 10.1016/j.tmaid.2020.101656.



716	Namendys-Silva SA. 2020a. ECMO for ARDS due to COVID-19. Heart & Lung. DOI
717	10.1016/j.hrtlng.2020.03.012.
718	Ñamendys-Silva SA. 2020b. Respiratory support for patients with COVID-19 infection. <i>The</i>
719	Lancet Respiratory Medicine 8:e18. DOI 10.1016/s2213-2600(20)30110-7.
720	Oliveira TC, Abranches MV, and Lana RM. 2020. (In)Segurança alimentar no contexto da
721	pandemia por SARS-CoV-2. Cadernos de saude publica 36. DOI 10.1590/0102-
722	311X00055220.
723	Ornell F, Schuch JB, Sordi AO, and Kessler FHP. 2020. "Pandemic fear" and COVID-19:
724	mental health burden and strategies. Brazilian Journal of Psychiatry. DOI 10.1590/1516
725	4446-2020-0008.
726	Ortega JT, Serrano ML, Pujol FH, and Rangel HR. 2020a. Role of changes in SARS-CoV-2
727	spike protein in the interaction with the human ACE2 receptor: An in silico analysis.
728	EXCLI journal 19:410-417. DOI 10.17179/excli2020-1167.
729	Ortega JT, Serrano ML, Pujol FH, and Rangel HR. 2020b. Unrevealing sequence and structural
730	features of novel coronavirus using in silico approaches: The main protease as molecular
731	target. EXCLI journal 19:400-409. DOI 10.17179/excli2020-1189.
732	Palacios Cruz M, Santos E, Velázquez Cervantes MA, and León Juárez M. 2020. COVID-19,
733	una emergencia de salud pública mundial. Revista Clínica Española. DOI
734	10.1016/j.rce.2020.03.001.
735	Picot S, Marty A, Bienvenu A-L, Blumberg LH, Dupouy-Camet J, Carnevale P, Kano S, Jones
736	MK, Daniel-Ribeiro CT, and Mas-Coma S. 2020. Coalition: Advocacy for prospective
737	clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-
738	19. One Health:100131. DOI 10.1016/j.onehlt.2020.100131.



739	Puliatti S, Eissa A, Eissa R, Amato M, Mazzone E, Dell'Oglio P, Sighinolfi MC, Zoeir A, Micali
740	S, Bianchi G, Patel V, Wiklund P, Coelho RF, Bernhard J-C, Dasgupta P, Mottrie A, and
741	Rocco B. 2020. COVID-19 and Urology: A Comprehensive Review of the Literature.
742	BJU International n/a. DOI 10.1111/bju.15071.
743	Quintão VC, Simões CM, Lima LHNe, Barros GAMd, Salgado-Filho MF, Guimarães GMN,
744	Alves RL, Caetano AMM, Schmidt AP, and Carmona MJC. 2020. The Anesthesiologist
745	and COVID-19. Brazilian Journal of Anesthesiology (English Edition). DOI
746	10.1016/j.bjane.2020.03.002.
747	Rascado Sedes P, Ballesteros Sanz MÁ, Bodí Saera MA, Carrasco Rodríguez-Rey LF,
748	Castellanos Ortega Á, Catalán González M, de Haro López C, Díaz Santos E, Escriba
749	Barcena A, Frade Mera MJ, Igeño Cano JC, Martín Delgado MC, Martínez Estalella G,
750	Raimondi N, Roca I Gas O, Rodríguez Oviedo A, Romero San Pío E, Trenado Álvarez J,
751	and Raurell M. 2020. Plan de contingencia para los servicios de medicina intensiva frente
752	a la pandemia COVID-19♦. <i>Enfermería Intensiva</i> . DOI 10.1016/j.enfi.2020.03.001.
753	Rodriguez-Morales AJ, Bonilla-Aldana DK, Tiwari R, Sah R, Rabaan AA, and Dhama K. 2020a.
754	COVID-19, an Emerging Coronavirus Infection: Current Scenario and Recent
755	Developments - An Overview. Journal of Pure and Applied Microbiology 14:05-12. DOI
756	10.22207/JPAM.14.1.02.
757	Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-
758	Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-
759	Paredes C, Henao-Martinez AF, Paniz-Mondolfi A, Lagos-Grisales GJ, Ramírez-Vallejo
760	E, Suárez JA, Zambrano LI, Villamil-Gómez WE, Balbin-Ramon GJ, Rabaan AA,
761	Harapan H, Dhama K, Nishiura H, Kataoka H, Ahmad T, Sah R, and Latin American



762	Network of Coronavirus Disease C-R. 2020b. Clinical, laboratory and imaging features
763	of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious
764	Disease. DOI 10.1016/j.tmaid.2020.101623.
765	Rodriguez-Morales AJ, Sah R, and Paniz-Mondolfi A. 2020c. Should the Holy Week 2020 be
766	cancelled in Latin America due to the COVID-19 pandemic? Travel Medicine and
767	Infectious Disease: 101633. DOI 10.1016/j.tmaid.2020.101633.
768	Rodriguez-Morales AJ, Sánchez-Duque JA, Hernández Botero S, Pérez-Díaz CE, Villamil-
769	Gómez WE, Méndez CA, Verbanaz S, Cimerman S, Rodriguez-Enciso HD, Escalera-
770	Antezana JP, Balbin-Ramon GJ, Arteaga-Livias FK, Cvetkovic-Vega A, Orduna T,
771	Savio-Larrea E, and Paniz-Mondolfi A. 2020d. Preparación y control de la enfermedad
772	por coronavirus 2019 (COVID-19) en América Latina. ACTA MEDICA PERUANA 37.
773	DOI 10.35663/amp.2020.371.909.
774	Rosa SGV, and Santos WC. 2020. Clinical trials on drug repositioning for COVID-19 treatment
775	Revista Panamericana De Salud Publica-Pan American Journal of Public Health 44.
776	DOI 10.26633/rpsp.2020.40.
777	Rosales-Mendoza S. 2020. Will plant-made biopharmaceuticals play a role in the fight against
778	COVID-19? Expert Opinion on Biological Therapy:null-null. DOI
779	10.1080/14712598.2020.1752177.
780	Saavedra-Velasco M, Chiara-Chilet C, Pichardo-Rodriguez R, Grandez-Urbina A, and Inga-
781	Berrospi F. 2020. Coinfección entre dengue y COVID-19: Necesidad de abordaje en
782	zonas endémicas. Revista de la Facultad de Ciencias Médicas de Córdoba 77. DOI
783	10.31053/1853.0605.v77.n1.28031.



784	Sabino-Silva R, Jardim ACG, and Siqueira WL. 2020. Coronavirus COVID-19 impacts to
785	dentistry and potential salivary diagnosis. Clinical Oral Investigations. DOI
786	10.1007/s00784-020-03248-x.
787	Sagulenko P, Puller V, and Neher RA. 2018. TreeTime: Maximum-likelihood phylodynamic
788	analysis. Virus evolution 4:vex042-vex042. DOI 10.1093/ve/vex042.
789	Sah R, Rodriguez-Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, Bastola A, Lal BK, Ojha HC,
790	Rabaan AA, Zambrano LI, Costello A, Morita K, Pandey BD, and Poon LLM. 2020.
791	Complete genome sequence of a 2019 novel coronavirus (SARS-COV-2) strain isolated
792	in Nepal. Microbiology Resource Announcements 9. DOI 10.1128/mra.00169-20.
793	Sawano T, Ozaki A, Rodriguez-Morales AJ, Tanimoto T, and Sah R. 2020. Limiting spread of
794	COVID-19 from cruise ships - lessons to be learnt from Japan. QJM: An International
795	Journal of Medicine. DOI 10.1093/qjmed/hcaa092.
796	Serafin MB, Bottega A, Foletto VS, da Rosa TF, Hörner A, and Hörner R. 2020. Drug
797	repositioning an alternative for the treatment of coronavirus COVID-19. International
798	Journal of Antimicrobial Agents: 105969. DOI 10.1016/j.ijantimicag.2020.105969.
799	Sifuentes-Rodriguez E, and Palacios-Reyes D. 2020. COVID-19: The outbreak caused by a new
800	coronavirus. Boletin Medico Del Hospital Infantil De Mexico 77:47-53. DOI
801	10.24875/bmhim.20000039.
802	Siordia JA. 2020. Epidemiology and Clinical Features of COVID-19: A Review of Current
803	Literature. Journal of Clinical Virology:104357. DOI 10.1016/j.jcv.2020.104357.
804	Stern D, López-Olmedo N, Pérez-Ferrer C, González-Morales R, Canto-Osorio F, and
805	Barrientos-Gutiérrez T. 2020. Revisión rápida del uso de cubrebocas quirúrgicos en



806	ambito comunitario e infecciones respiratorias agudas. Salud Publica de Mexico. DOI
807	10.21149/11379.
808	Torales J, Higgins M, Castaldelli-Maia JM, and Ventriglio A. 2020. The outbreak of COVID-19
809	coronavirus and its impact on global mental health. International Journal of Social
810	Psychiatry:20764020915212-20764020915212. DOI 10.1177/0020764020915212.
811	Torres I, and Sacoto F. 2020. Localising an asset-based COVID-19 response in Ecuador. The
812	Lancet. DOI 10.1016/S0140-6736(20)30851-5.
813	Trujillo A. 2020. Response to Wen and Li. Anesthesia Procedure of Emergency Operation for
814	Patients with Suspected or Confirmed COVID-19 (DOI: 10.1089/sur.2020.040). Surg
815	infect,(Larchmt). DOI 10.1089/sur.2020.088.
816	van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin
817	A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, and Munster VJ.
818	2020. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.
819	New England Journal of Medicine. DOI 10.1056/NEJMc2004973.
820	Vega-Vega O, Arvizu-Hernández M, Domínguez-Cherit JG, Sierra-Madero J, and Correa-Rotter
821	R. 2020. Prevención y control de la infección por coronavirus SARS-CoV-2 (Covid-19)
822	en unidades de hemodiálisis. Salud Pública de México. DOI 10.21149/11330.
823	Wu D, Wu T, Liu Q, and Yang Z. 2020. The SARS-CoV-2 outbreak: What we know.
824	International Journal of Infectious Diseases 94:44-48. DOI 10.1016/j.ijid.2020.03.004.
825	Xu B, Gutierrez B, Mekaru S, Sewalk K, Goodwin L, Loskill A, Cohn EL, Hswen Y, Hill SC,
826	Cobo MM, Zarebski AE, Li S, Wu CH, Hulland E, Morgan JD, Wang L, O'Brien K,
827	Scarpino SV, Brownstein JS, Pybus OG, Pigott DM, and Kraemer MUG. 2020.





828	Epidemiological data from the COVID-19 outbreak, real-time case information. Scientific
829	Data 7. DOI 10.1038/s41597-020-0448-0.
830	Zambrano LI, Fuentes-Barahona IC, Bejarano-Torres DA, Bustillo C, Gonzales G, Vallecillo-
831	Chinchilla G, Sanchez-Martínez FE, Valle-Reconco JA, Sierra M, Bonilla-Aldana DK,
832	Cardona-Ospina JA, and Rodríguez-Morales AJ. 2020. A pregnant woman with COVID-
833	19 in Central America. Travel Medicine and Infectious Disease:101639. DOI
834	10.1016/j.tmaid.2020.101639.
835	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan
836	F, Ma X, Wang D, Xu W, Wu G, Gao GF, and Tan W. 2020. A novel coronavirus from
837	patients with pneumonia in China, 2019. New England Journal of Medicine 382:727-733
838	DOI 10.1056/NEJMoa2001017.
839	
840	



PRISMA Flow diagram of selection process of COVID-19 or SAR-CoV-2 publications containing researchers with Latin American affiliation.

Identification stage was performed on April 10, 2020.






PRISMA 2009 Flow Diagram

Identification

Screening

Eligibility


Included





Classification of publications by category


Other publications refer to: Consensus statement, Contribution, and Technical note.





Classification of publications according to the national affiliation.


Several authors from the same country in a publication were counted as one contribution to the country. Publications with authors from different countries were counted as one for each country. Latin American countries not shown had no publications until April 10, 2020.





Classification of publications by topic.

Medical considerations refer to surgery recommendations, diagnosis, comorbidities, medical guidelines, dentistry considerations, among others. The general aspects include zoonotic links, spreading, origin, disease, surveillance, among others. Bioinformatics refers to molecular and phylogenetic analyses, molecular simulations, genetic annotations, among others.





Phylogenetic location of genome sequences of some strains isolated in Latin America in the SARS-CoV-2 phylogenetic tree.

The phylogenetic tree was generated and adapted from the GISAID database (Hadfield *et al.*, 2018; Sagulenko *et al.*, 2018). The tree was retrieved on April 20, 2020.






Table 1(on next page)

Summary of the COVID-19 outbreak affectation in the Latin American countries.

Total cases and total deaths are reported until April 20, 2020 (Johns Hopkins University 2020).



Country	First case	Cases	Deaths
Argentina	Mar 3	2941	136
Bolivia	Mar 10	564	33
Brazil	Feb 25	40581	2845
Chile	Mar 3	10507	139
Colombia	Mar 6	3963	189
Costa Rica	Mar 6	662	6
Cuba	Mar 11	1087	36
Dominican Rep.	Mar 1	4964	235
Ecuador	Feb 14	10128	507
El Salvador	Mar 18	218	7
Guatemala	Mar 13	289	7
Haiti	Mar 2	47	3
Honduras	Mar 11	477	46
Mexico	Feb 27	8261	686
Nicaragua	Mar 18	10	2
Panama	Mar 8	4467	126
Paraguay	Mar 7	208	8
Peru	Mar 6	16325	445
Uruguay	Mar 13	528	10
Venezuela	Mar 13	256	9
	Total	106483	5475



Table 2(on next page)

Summary of genome sequences of SARS-CoV-2 strains isolated in Latin America and collected in GISAID database.

Information updated on April 20, 2020 (Hadfield et al. 2018; Sagulenko et al. 2018).



Country	Submitting lab	Location	Total
Argentina	Instituto Nacional Enfermedades Infecciosas C.G.Malbran	Argentina	3
Brazil	Bioinformatics Laboratory - LNCC	Goiais	1
		Minas Gerais	5
		Rio de Janeiro	7
		Rio Grande do Sul	1
		São Paulo	4
	Instituto Adolfo Lutz, Interdiciplinary Procedures Center,	Brasilia	1
	Strategic Laboratory	Sao Paulo	2
		Sao Paulo	11
	Instituto Oswaldo Cruz FIOCRUZ - Laboratory of Respiratory	Maceio	1
	Viruses and Measles (LVRS)	Feira de Santana	2
		Brasilia	5
		Vila Velha	1
		Niteroi	1
		Rio de Janeiro	6
		Florianopolis	1
		Joinville	1
	Laboratorio de Ecologia de Doencas Transmissiveis na	Manaus	1
	Amazonia, Instituto Leonidas e Maria Deane - Fiocruz Amazonia		
	Laboratory of Virology	Brasilia	1
Chile	Instituto de Salud Publica de Chile	Santiago	2
		Talca	2
	MSHS Pathogen Surveillance Program	Santiago	3
Colombia	Instituto Nacional de Salud Universidad Cooperativa de	Antioquia	1
	Colombia Instituto Alexander von Humboldt Imperial College-	Bogota	1
	London London School of Hygiene & Tropical Medicine	_	
Ecuador	Institute of Microbiology, Universidad San Francisco de Quito	Pichincha	3
		Quito	1
Mexico	Instituto de Diagnostico y Referencia Epidemiologicos (INDRE)	Chiapas	1
		Estado de Mexico	1
		Mexico City	2
		Puebla	1
		Queretaro	1
	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	Mexico City	5
	Instituto Nacional de Enfermedades Respiratorias	Mexico City	5
	Laboratorio Central de Epidemiología-DLVIE / Laboratorio de Secuenciación-Centro de Instrumentos. Instituto Mexicano del Seguro Social	Chihuahua	1
Nepala	The University of Hong Kong	Kathmandu	1
Panama	Gorgas Memorial Institute for Health Studies	Panama City	1
Peru Laboratorio de Referencia Nacional de Biotecnologia y Biologia Molecular. Instituto Nacional de Salud Peru		Lima	2
Uruguay	Microbial Genomics Laboratory, Institut Pasteur Montevideo	Montevideo	9
	· · · · · · · · · · · · · · · · · · ·	Total general	98

- a Nepal was included due to researchers with Colombian and Honduran affiliations contributed in
- 2 its genome sequencing (Sah et al. 2020).